Spots Global Cancer Trial Database for PF-07284892 in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PF-07284892 in Participants With Advanced Solid Tumors
Official Title: A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Study ID: NCT04800822
Conditions
Study Description
Brief Summary: The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
Mayo Clinic, Scottsdale, Arizona, United States
California Cancer Associates for Research and Excellence, Encinitas, California, United States
California Cancer Associates for Research and Excellence, San Marcos, California, United States
University of Iowa, Iowa City, Iowa, United States
Henry Ford Hospital, Detroit, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Henry Ford Medical Center - Columbus, Novi, Michigan, United States
Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care, New York, New York, United States
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York, New York, United States
Tennessee Oncology PLLC, Franklin, Tennessee, United States
Tennessee Oncology, PLLC, Franklin, Tennessee, United States
Sarah Cannon Research Institute- Pharmacy, Nashville, Tennessee, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
